Neurogene (NGNE) Non-Current Deferred Tax Liability (2013 - 2014)
Neurogene posted quarterly Non-Current Deferred Tax Liability of $1.8 million for Q4 2014, little changed year-on-year from $1.8 million in Q4 2013, and little changed on a QoQ basis from $1.8 million in Q1 2014.
Neurogene (NGNE) has 2 years of Non-Current Deferred Tax Liability data on file, last reported at $1.8 million in Q4 2014.
- For the quarter ending Q4 2014, Non-Current Deferred Tax Liability changed 0.02% year-over-year to $1.8 million; the trailing twelve-month figure through Dec 2014 stood at $1.8 million (changed 0.02% YoY), and the FY2014 full-year result was $1.8 million, changed 0.02% from the prior year.
- Non-Current Deferred Tax Liability for Q4 2014 stood at $1.8 million, roughly flat from $1.8 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $1.8 million in Q4 2013 and bottomed at $1.8 million in Q4 2014.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Neurogene | 632.14 Mn | 632.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | 1.80 Mn |
| Dec 31, 2014 | 1.80 Mn |
| Mar 31, 2014 | 1.80 Mn |
| Mar 31, 2014 | 1.80 Mn |
| Dec 31, 2013 | 1.80 Mn |
| Dec 31, 2013 | 1.80 Mn |